140 related articles for article (PubMed ID: 8737571)
1. Optimization of environmental factors for the production and handling of recombinant retrovirus.
Lee SG; Kim S; Robbins PD; Kim BG
Appl Microbiol Biotechnol; 1996 May; 45(4):477-83. PubMed ID: 8737571
[TBL] [Abstract][Full Text] [Related]
2. Closed hollow-fiber bioreactor: a new approach to retroviral vector production.
Pan D; Whitley CB
J Gene Med; 1999; 1(6):433-40. PubMed ID: 10753069
[TBL] [Abstract][Full Text] [Related]
3. An improved method for generating retroviral producer clones for vectors lacking a selectable marker gene.
Persons DA; Mehaffey MG; Kaleko M; Nienhuis AW; Vanin EF
Blood Cells Mol Dis; 1998 Jun; 24(2):167-82. PubMed ID: 9642098
[TBL] [Abstract][Full Text] [Related]
4. Retroviral end-point titer is not predictive of gene transfer efficiency: implications for vector production.
Forestell SP; Böhnlein E; Rigg RJ
Gene Ther; 1995 Dec; 2(10):723-30. PubMed ID: 8750011
[TBL] [Abstract][Full Text] [Related]
5. Stoichiometric limitations in assembly of active recombinant retrovirus.
Lei P; Andreadis ST
Biotechnol Bioeng; 2005 Jun; 90(7):781-92. PubMed ID: 15812799
[TBL] [Abstract][Full Text] [Related]
6. Production of high-titer retroviral vectors and detection of replication-competent retroviruses.
Kim YS; Lim HK; Kim KJ
Mol Cells; 1998 Feb; 8(1):36-42. PubMed ID: 9571629
[TBL] [Abstract][Full Text] [Related]
7. Optimized conditions for the production of recombinant amphotropic retroviral vector preparations.
Kaptein LC; Greijer AE; Valerio D; van Beusechem VW
Gene Ther; 1997 Feb; 4(2):172-6. PubMed ID: 9081708
[TBL] [Abstract][Full Text] [Related]
8. Production of increased titer retrovirus vectors from stable producer cell lines by superinfection and concentration.
Parente MK; Wolfe JH
Gene Ther; 1996 Sep; 3(9):756-60. PubMed ID: 8875222
[TBL] [Abstract][Full Text] [Related]
9. Sorting vector producer cells for high transgene expression increases retroviral titer.
Beaudoin EL; Bais AJ; Junghans RP
J Virol Methods; 2008 Mar; 148(1-2):253-9. PubMed ID: 18249448
[TBL] [Abstract][Full Text] [Related]
10. Increased viral titer through concentration of viral harvests from retroviral packaging lines.
Paul RW; Morris D; Hess BW; Dunn J; Overell RW
Hum Gene Ther; 1993 Oct; 4(5):609-15. PubMed ID: 7506579
[TBL] [Abstract][Full Text] [Related]
11. Transgene inheritance and retroviral infection contribute to the efficiency of gene expression in solid tumors inoculated with retroviral vector producer cells.
Tamiya T; Wei MX; Chase M; Ono Y; Lee F; Breakefield XO; Chiocca EA
Gene Ther; 1995 Oct; 2(8):531-8. PubMed ID: 8593603
[TBL] [Abstract][Full Text] [Related]
12. [Large-scale real-time titration of green-fluorescence-protein-marked recombinant retrovirus: comparison with standard titration method].
Jiang QL; Wang JM; Jiang S; Wen LM; Zhou H
Di Yi Jun Yi Da Xue Xue Bao; 2003 Oct; 23(10):1101-3. PubMed ID: 14559708
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the relative level of gene expression from different retroviral vectors used for gene therapy.
Byun J; Kim SH; Kim JM; Yu SS; Robbins PD; Yim J; Kim S
Gene Ther; 1996 Sep; 3(9):780-8. PubMed ID: 8875226
[TBL] [Abstract][Full Text] [Related]
14. Recombinant retroviral vector interferes with the detection of amphotropic replication competent retrovirus in standard culture assays.
Printz M; Reynolds J; Mento SJ; Jolly D; Kowal K; Sajjadi N
Gene Ther; 1995 Mar; 2(2):143-50. PubMed ID: 7719931
[TBL] [Abstract][Full Text] [Related]
15. Packaging cell line characteristics and optimizing retroviral vector titer: the National Gene Vector Laboratory experience.
Reeves L; Smucker P; Cornetta K
Hum Gene Ther; 2000 Oct; 11(15):2093-103. PubMed ID: 11044911
[TBL] [Abstract][Full Text] [Related]
16. Integrated strategy for the production of therapeutic retroviral vectors.
Carrondo M; Panet A; Wirth D; Coroadinha AS; Cruz P; Falk H; Schucht R; Dupont F; Geny-Fiamma C; Merten OW; Hauser H
Hum Gene Ther; 2011 Mar; 22(3):370-9. PubMed ID: 21043806
[TBL] [Abstract][Full Text] [Related]
17. kat: a high-efficiency retroviral transduction system for primary human T lymphocytes.
Finer MH; Dull TJ; Qin L; Farson D; Roberts MR
Blood; 1994 Jan; 83(1):43-50. PubMed ID: 8274751
[TBL] [Abstract][Full Text] [Related]
18. Improved titers of retroviral vectors from the human FLYRD18 packaging cell line in serum- and protein-free medium.
Gerin PA; Gilligan MG; Searle PF; Al-Rubeai M
Hum Gene Ther; 1999 Aug; 10(12):1965-74. PubMed ID: 10466630
[TBL] [Abstract][Full Text] [Related]
19. A microfluidic bioreactor for increased active retrovirus output.
Vu HN; Li Y; Casali M; Irimia D; Megeed Z; Yarmush ML
Lab Chip; 2008 Jan; 8(1):75-80. PubMed ID: 18094764
[TBL] [Abstract][Full Text] [Related]
20. Effects of culture parameters on the production of retroviral vectors by a human packaging cell line.
McTaggart S; Al-Rubeai M
Biotechnol Prog; 2000; 16(5):859-65. PubMed ID: 11027182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
